Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec 1;194(11):1435-1436.
doi: 10.1164/rccm.201607-1464LE.

Reply: Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung Diseases

Jiangning Tan  1 , Daniel J Kass  1
Affiliations
Comment

Reply: Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung Diseases

Jiangning Tan et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382–1389. - PubMed
    1. Tan J, Tedrow JR, Dutta JA, Juan-Guardela B, Nouraie M, Chu Y, Trejo Bittar H, Ramani K, Biswas PS, Veraldi KL, et al. Expression of RXFP1 is decreased in idiopathic pulmonary fibrosis: implications for relaxin-based therapies. Am J Respir Crit Care Med. 2016;194:1392–1402. - PMC - PubMed
    1. Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, et al. Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60:1102–1111. - PMC - PubMed